Shandong Tianli Pharmaceutical 40,000 tons/year VC-Na New and Old Kinetic Energy Conversion Project

I. Project Name

Shandong Tianli Pharmaceutical .40,000 Tons/Year VC-Na New and Old Kinetic Energy Conversion Project

II. Project Company Introduction

Shandong Tianli Pharmaceutical , founded in 1994, is a Sino-foreign joint venture invested by Shandong Lianmeng Chemical Group and Singapore's Suntek Group. It specializes in biochemical and pharmaceutical production and sales. It is the first domestic enterprise with a complete corn deep-processing industry chain, from corn starch to sorbitol (mannitol) and then to vitamin C. It is Asia's largest sugar alcohol producer and a key player in the global vitamin C market. The company covers an area of ​​1,100 mu (approximately 73 hectares), has total assets of 1.76 billion yuan, and employs 1,885 people.

III. Project Content and Construction Scale

The project involves the construction of a new VC-Na production line, and the purchase of 425 sets of related production equipment, including seed tanks, fermentation tanks, ultrafiltration and nanofiltration units, evaporators, heat exchangers, ester transfer tanks, and centrifuges. Upon completion, the project will have an annual production capacity of 40,000 tons of VC-Na.

IV. Project Construction Conditions

The project has been approved and is currently undergoing environmental impact assessment. Land use permits are complete, and the construction unit has sufficient funds.

V. Total Project Investment

US$99.14 million

VI. Market and Economic Benefit Analysis and Forecast

After the project is fully operational, it is expected to generate an additional RMB 2.25 billion in annual sales revenue and RMB 590 million in profit.

VII. Cooperation Method

Joint venture, cooperation

VIII. Contact Information

Source: Shandong Provincial Development and Reform Commission